1-9 of 9
Andrew Hammes, MS
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Venetoclax and Azacitidine for Newly Diagnosed Non-Elderly Adult Patients with Acute Myeloid Leukemia and Adverse Risk Features

Jonathan A. Gutman, MD, Amanda Winters, MDPhD, Maria L Amaya, MD PhD, Christine M. McMahon, MD, Jeffrey Schowinsky, MD, Diana Abbott, PhD, Andrew Hammes, MS, Shanshan Pei, PhD, Brett M. Stevens, PhD, Craig T. Jordan, PhD, Clayton Smith, MD, Daniel A. Pollyea
Journal: Blood
Blood (2020) 136 (Supplement 1): 9.
https://doi.org/10.1182/blood-2020-136120
Published: 2020
Journal Articles

Outcomes Following Allogeneic Stem Cell Transplantation for AML in First Completion Remission Are Comparable between MRD Negative Patients and MRD Positive Patients Receiving Induction Only and Are Superior to MRD Positive Patients Receiving Induction and Additional Therapy

Jonathan A Gutman, MD, Prashant Sharma, MD, Enkhtsetseg Purev, MD, Clayton Smith, MD, Amanda Winters, MD PhD, Andrew Hammes, MS, Michael R. Loken, PhD, Daniel A Pollyea, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4615.
https://doi.org/10.1182/blood-2019-129150
Published: 2019
Journal Articles

Developmental Plasticity of Acute Myeloid Leukemia Mediates Resistance to Venetoclax-Based Therapy

Shanshan Pei, PhD, Daniel A Pollyea, MD, Annika Gustafson, Mohammad Minhajuddin, PhD, Brett M. Stevens, PhD, Haobin Ye, PhD, Anagha Inguva, BSc, Maria L Amaya, MD PhD, Anna Krug, BS, Courtney L Jones, PhD, Biniam Adane, PhD, Amanda Winters, MD PhD, Nabilah Khan, Jessica Ponder, PhD, Jeffrey Schowinsky, Andrew Hammes, MS, Diana Abbott, PhD, Jason R Myers, MS, John M Ashton, PhD, Jonathan A Gutman, MD, Enkhtsetseg Purev, MD PhD, Haley E. Ramsey, PhDMSc, Michael R. Savona, MD, Stephen W. Fesik, PhD, Clayton Smith, MD, Craig T Jordan, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 185.
https://doi.org/10.1182/blood-2019-131390
Published: 2019
Journal Articles

Broad Efficacy of the Translation Inhibitor Omacetaxine in Relapsed/Refractory Multiple Myeloma Samples

Zachary J Walker, BS, MS, Beau M Idler, BA, Michael J VanWyngarden, BS, Brett M. Stevens, PhD, Shelby C Bearrows, BS, Lorraine N Davis, BS, Andrew Hammes, MS, Clayton Smith, MD, Craig T Jordan, PhD, Tomer M Mark, MD MS, Peter A Forsberg, MD, Daniel W Sherbenou, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4404.
https://doi.org/10.1182/blood-2019-121937
Published: 2019
Journal Articles

How Median Follow-up Time Informs Survival Outcomes: Lessons from a Trial of Acute Myeloid Patients Treated with Venetoclax and Azacitidine

Diana Abbott, PhD, Andrew Hammes, MS, Jonathan A Gutman, MD, Daniel A Pollyea, MD, Clayton Smith, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5897.
https://doi.org/10.1182/blood-2019-126344
Published: 2019
Journal Articles

Venetoclax and Azacitidine for Older Newly Diagnosed Patients with Acute Myeloid Leukemia: A Single-Institution Pilot Study Using Measurable Residual Disease to Guide Therapy

Amanda Winters, MD PhD, Jonathan A Gutman, MD, Enkhtsetseg Purev, MD PhD, Brett M. Stevens, PhD, Shanshan Pei, PhD, Jeffrey Schowinsky, Diana Abbott, PhD, Andrew Hammes, MS, Molly Nakic, Lindsey Lyle, Keri Halsema, Dwight Macero, PA-C, Alex Hirose, Chelsey Boggs, Angie Falco, Natalie Monson, Shirstine Rahkola, Sarah Wright, Tyler D'Ovidio, Clayton Smith, MD, Craig T Jordan, PhD, Daniel A Pollyea, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2638.
https://doi.org/10.1182/blood-2019-122120
Published: 2019
Journal Articles

Relapsed Acute Myeloid Leukemia Is Less Sensitive to Venetoclax + Azacitidine Due to Leukemia Stem Cell Resistance Driven By Fatty Acid Metabolism and Can be Overcome By Pharmacologic Inhibition of CPT1

Daniel A Pollyea, MD, Courtney L Jones, PhD, Brett M Stevens, PhD, Shanshan Pei, PhD, Angelo D'Alessandro, PhD, Rachel Culp-Hill, BS, Diana Abbott, PhD, Andrew Hammes, MS, James Dugan, MD, Jonathan A Gutman, MD, Enkhtsetseg Purev, MD PhD, Clayton Smith, MD, Craig T Jordan, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 432.
https://doi.org/10.1182/blood-2018-99-111507
Published: 2018
Journal Articles

Cellular Proliferation By Multiplex Immunohistochemistry Identifies Aggressive Disease Behavior in Relapsed Multiple Myeloma

Peter A. Forsberg, MD, Tomer M Mark, MDMSc, Daniel W. Sherbenou, MDPhD, Andrew Hammes, MS, Adriana C. Rossi, MDMSc, Ruben Niesvizky, MD, David S Jayabalan, MSc, Scott Ely, MDMPH
Journal: Blood
Blood (2017) 130 (Supplement 1): 3059.
https://doi.org/10.1182/blood.V130.Suppl_1.3059.3059
Published: 2017
Journal Articles

Sequential Azacitidine (Aza) and Lenalidomide (Len) for Patients (Pts) with Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML): Clinical Results and Predictive Modeling Using Computational Analysis and Serial Genomics

Brett M. Stevens, PhD, Amanda Winters, MD PhD, Jonathan A Gutman, MD, Aaron Fullerton, BS, Gregory Hemenway, MS2, Nicholas Miltgen, BS, Qi Wei, MD, Taher Abbasi, MS, MBA, Shireen Vali, PhD, Neeraj Kumar Singh, B.Tech, Leylah M. Drusbosky, PhD, Chris R. Cogle, MD, Andrew Hammes, MS, Craig T. Jordan, PhD, Daniel A. Pollyea, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1337.
https://doi.org/10.1182/blood.V130.Suppl_1.1337.1337
Published: 2017